The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7301-7309

  Carroll, F Ivy ^a   Abraham, Philip ^a   Gong, Paul K ^a   Pidaparthi, Ramakrishna R ^a   Blough, Bruce E ^a   Che, Yingni ^b   Hampton, Amber ^b   Gunnell, Melinda ^b   Lay Jr , Jackson O ^c   Peterson, Eric C ^b   Owens, S Michael ^b  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 CARBOXYPENTYLOXY)METHAMPHETAMINE; 3 (9 CARBOXYNONYLOXY)METHAMPHETAMINE; HAPTEN; METHAMPHETAMINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; DRUG ABUSE; DRUG SPECIFICITY; DRUG SYNTHESIS; SYNTHESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CATTLE; CELL LINE; DRUG DISCOVERY; FEMALE; HAPTENS; IMMUNIZATION; METHAMPHETAMINE; MICE; OVALBUMIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTANCE-RELATED DISORDERS; SUBSTRATE SPECIFICITY;

EID: 70949094408     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901134w     Document Type: Article

References (19)

1. The Meth Epidemic in America; National Association of Counties, 2005.
2. Murray, J. B. Psychophysiological aspects of amphetamine-methamphetamine abuse. J. Psychol. 1998, 132, 227-237.
3. United Nations Office of Drug Control and Crime Prevention. Methamphetamine; World Drug Report 2000; Oxford University Press: New York, 2000; pp 99-121.
4. Nicosia, N.; Pacula, R. L.; Kilmer, B.; Lundberg, R.; Chiesa, J. The Economic Cost of Methamphetamine Use in the United States, 2005; RAND Corporation: Santa Monica, CA, 2009.
5. Results from the 2008 National Survey on Drug Use and Health: National Findings; Substance Abuse and Mental Health Services Administration - Office of Applied Studies: Rockville, MD, 2009.
6. Substance Abuse and Mental Health Services Administration Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Departments Visits; U.S. Department of Health and Human Services, Office of Applied Studies: Washington, DC, 2005.
7. Xu, Y.; Hixon, M. S.; Yamamoto, N.; McAllister, L. A.; Wentworth, A. D.; Wentworth, P., Jr.; Janda, K. D. Antibody-catalyzed anaerobic destruction of methamphetamine. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 3681-3686.
8. Cho, A. K.; Ice, A. New dosage form of an old drug. Science 2009, 249, 631-634.
9. Thrash, B.; Karuppagounder, S. S.; Uthayathas, S.; Suppiramaniam, V.; Dhanasekaran, M. Neurotoxic effects of methamphetamine. Neurochem. Res. 2009, DOI: 10.1007/s11064-009-0042-5.
10. Peterson, E. C.; Gunnell, M.; Che, Y.; Goforth, R. L.; Carroll, F. I.; Henry, R.; Liu, H.; Owens, S. M. Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse. J. Pharmacol. Exp. Ther. 2007, 322, 30-39.
11. Nichols, D. E.; Barfknecht, C. F.; Rusterholz, D. B.; Benington, F.; Morin, R. D. Asymmetric synthesis of psychotomimetic phenylisopropylamines. J. Med. Chem. 1973, 16, 480-483.
12. Owens, S. M.; Zorbas, M.; Lattin, D. L.; Gunnell, M.; Polk, M. Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. J. Pharmacol. Exp. Ther. 1988, 246, 472-478.
13. Peterson, E. C.; Laurenzana, E. M.; Atchley, W. T.; Hendrickson, H. P.; Owens, S. M. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J. Pharmacol. Exp. Ther. 2008, 325, 124-133.
14. Gentry, W. B.; Ruedi-Bettschen, D.; Owens, S. M. Development of active and passive human vaccines to treat methamphetamine addiction. Hum. Vaccines 2009, 5, 206-213.
15. Davis, M. T.; Preston, J. F. A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking. Anal. Biochem. 1981, 116, 402-407.
16. Valentine, J. L.; Arnold, L. W.; Owens, S. M. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J. Pharmacol. Exp. Ther. 1994, 269, 1079-1085.
17. Valentine, J. L.; Owens, S. M. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J. Pharmacol. Exp. Ther. 1996, 278, 717-724.
18. Hardin, J. S.; Wessinger, W. D.; Proksch, J. W.; Owens, S. M. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J. Pharmacol. Exp. Ther. 1998, 285, 1113-1122.
19. McMillan, D. E.; Hardwick, W. C.; Li, M.; Gunnell, M. G.; Carroll, F. I.; Abraham, P.; Owens, S. M. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J. Pharmacol. Exp. Ther. 2004, 309, 1248-1255.